Syndax Pharmaceuticals, Inc.
SNDX
$18.79
-$0.33-1.73%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 60.39% | 42.70% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 20.85% | 89.39% | |||
| Cost of Revenue | -89.96% | 7,075.82% | |||
| Gross Profit | 254.58% | -233.36% | |||
| SG&A Expenses | 2.54% | 6.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.74% | 3.63% | |||
| Operating Income | 17.20% | 16.95% | |||
| Income Before Tax | 15.49% | 15.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 15.49% | 15.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.49% | 15.32% | |||
| EBIT | 17.20% | 16.95% | |||
| EBITDA | 17.20% | 16.95% | |||
| EPS Basic | 15.78% | 15.48% | |||
| Normalized Basic EPS | 15.77% | 15.49% | |||
| EPS Diluted | 15.78% | 15.48% | |||
| Normalized Diluted EPS | 15.77% | 15.49% | |||
| Average Basic Shares Outstanding | 0.33% | 0.19% | |||
| Average Diluted Shares Outstanding | 0.33% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||